Insider trade

CEO sold ~$2.25M of ROIV shares in the open market

Traded Oct 8, 2025 · Filed Oct 9, 2025

Why it stands out

The boss of Roivant Sciences sold $2.25M of Roivant Sciences shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

CEO$1M+Pre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$2,245,352

Shares × reported transaction price

Timing vs results

58 days after results of Aug 11, 2025, 33 days before results of Nov 10, 2025

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+7.6%	+1.7%	+5.9%
30 days	+32.0%	+4.3%	+27.6%
90 days	+35.8%	+5.6%	+30.2%
180 days	+75.6%	+3.5%	+72.1%

Past results only. Not a forecast.

The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.

11mo ago

Derivative exercise or conversion — not an open-market buy.

Scheduled in advance11mo ago

11mo ago

Derivative exercise or conversion — not an open-market buy.